Dr. Tam on Results of the CAPTIVATE Trial in CLL

Dec 8, 2019

By Constantine S. Tam, MD, MBBS

Conference|ASH Annual Meeting and Exposition

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

<<< View more from the 2019 ASH Annual Meeting

Related Videos

Related Content

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Related Content

Liso-cel Meets CR End Point in Relapsed/Refractory CLL/SLL

January 26th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.